Safety and tolerability of bireociclib for the treatment of advanced solid tumors as monotherapy and in combination with endocrine therapy: a multicenter, open-label, phase 1 clinical trial
Authors
Xianghui Duan
Huiping Li
Min Yan (ORCID: https://orcid.org/0000-0002-3911-748X)
Tao Sun (ORCID: https://orcid.org/0000-0001-5931-386X)
Safety and tolerability of bireociclib for the treatment of advanced solid tumors as monotherapy and in combination with endocrine therapy: a multicenter, open-label, phase 1 clinical trial
Xianghui Duan, Huiping Li, Min Yan, Tao Sun et al.
Citations
1 citations
Journal
BMC Medicine
Topics
Advanced Breast Cancer Therapies
Field-Weighted Citation Impact (FWCI)
1.52
article
Safety and tolerability of bireociclib for the treatment of advanced solid tumors as monotherapy and in combination with endocrine therapy: a multicenter, open-label, phase 1 clinical trial
Hebei Medical University (CN), Central South University (CN), Sun Yat-sen University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking University (CN), Tianjin Medical University Cancer Institute and Hospital (CN), Zhengzhou University (CN), National Cancer Center (US), Fudan University Shanghai Cancer Center (CN), Peking University Cancer Hospital (CN), 307th Hospital of Chinese People’s Liberation Army (CN), Sun Yat-sen Memorial Hospital (CN), Beijing Biocytogen (China) (CN), Fourth Hospital of Hebei Medical University (CN), Third Hospital of Nanchang (CN), Hunan Cancer Hospital (CN), Sichuan Cancer Hospital (CN), First Hospital of China Medical University (CN), Henan Cancer Hospital (CN), The 309th Hospital of Chinese People's Liberation Army (CN), First Bethune Hospital of Jilin University (CN), Ministry of Education (ET), Liaoning Cancer Hospital & Institute (CN), Chinese People’s Liberation Army 263 hospital (CN), China Medical University (CN)